Acute Liver Failure

Can-Fite BioPharma (NYSE: CANF) reports new data from Phase 2 trial evaluating namodenoson in advanced liver cancer, including the overall survival of nearly four years in two patients under treatment. Additional findings show the disappearance of ascites (abnormal buildup of fluid...

Shares of Vital Therapies Inc (NASDAQ: VTL), a biotherapeutic company that focuses on treatment for all forms of acute liver failure, have lost more than 60 percent over the past year, likely prompting Vetr top raters to take advantage of the recent weakness. Vetr top raters upgraded Vital...